US › Healthcare

Obsidian Therapeutics, Inc. Common Stock (OBX)

US · Healthcare · Biotechnology

$13.87+44.43%

Last close · 2026-11-06

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-19.6M

EPS

$-3.26

Key statistics

Market cap

$678.9M

Forward P/E

0.0

P/B

0.00

Book value

$-13.51

EPS (TTM)

$-1.63

52-week high

$49.97

52-week low

$9.60

50-day MA

$15.07

200-day MA

$17.18

Beta

3.06

Analyst view

Analysts rate Obsidian Therapeutics, Inc. Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $39.00.

Shareholding

Insiders

0.81%

Institutions

39.45%

Recent filings & reports

Document	Date
Quarterly report · Q2 2026 OBSIDIAN THERAPEUTICS, INC. — 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company formed April 10, 2026; merger completed August 3, 2026 (s	2026-08-14
Results announced · Q3 2026 OBSIDIAN BIOPHARMACEUTICAL - COMPANY SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Net losses: $100.6 million (year ended December 31, 2025) and $	2026-08-03

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Obsidian Therapeutics, Inc. Common Stock — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.